EGFR Exon 19 (Deletion)
About
Gene context: EGFR
Biomarker Type: Somatic Variant
Present: True
Chromosome: 7
Variant Annotation: Deletion
Exon: 19
Requires Oncogenic: True
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Dacomitinib | |
| FDA (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Erlotinib | |
| FDA (1) HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Gefitinib | |
| FDA (3) HC (3) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Osimertinib | |
| FDA (1) HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Carboplatin, Osimertinib, Pemetrexed | |
| FDA (1) HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Cisplatin, Osimertinib, Pemetrexed | |
| FDA (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Erlotinib, Ramucirumab | |
| FDA (2) HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Amivantamab, Lazertinib | |
| FDA (1) HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed | |
| FDA (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Datopotamab deruxtecan |